Literature DB >> 12940825

The burden of brain diseases in Europe.

J Olesen1, M Leonardi.   

Abstract

The burden [as defined by the World Health Organisation (WHO)] of brain diseases (neurological, neurosurgical and psychiatric diseases together) is very high and yet resources spent on these diseases are not necessarily commensurate with the extent of this burden. However, hard data on the burden of brain diseases in Europe have not previously been easily accessible. The Global Burden of Disease (GBD) 1990 study conducted jointly by the WHO, Harvard University and the World Bank provided new measures that are now becoming universally accepted and have been used also in a repeat study: The GBD 2000. The key parameter of the study is disability adjusted life years (DALY), which is the sum of years of life lost (YLL) caused by premature death and years of life lived with disability (YLD). In the present report, data from the GBD 2000 study and from the World Health Report 2001 on brain diseases is extracted for the territory of Europe. This territory corresponds roughly to the membership countries of the European Federation of Neurological Societies. The WHO's Report has a category called neuropsychiatric diseases, which comprises the majority but not all the brain diseases. In order to gather all brain diseases, stroke, meningitis, half of the burden of injuries and half of the burden of congenital abnormalities are added. Throughout Europe, 23% of the years of healthy life is lost and 50% of YLD are caused by brain diseases. Regarding the key summary measure of lost health, DALY, 35% are because of brain diseases. The fact that approximately one-third of all burden of disease is caused by brain diseases should have an impact on resource allocation to teaching, reasearch, health care and prevention. Although other factors are also of importance, it seems reasonable that one-third of the curriculum at medical school should deal with the brain and that one-third of life science funding should go to basic and clinical neuroscience. In addition, resource allocation to prevention, diagnosis and treatment of brain diseases should be increased to approach, at least, one-third of health care expenditure. With the present data on hand, neurologists, neurosurgeons, psychiatrists, patient organizations and basic neuroscientists have a better possibility to increase the focus on the brain.

Entities:  

Mesh:

Year:  2003        PMID: 12940825     DOI: 10.1046/j.1468-1331.2003.00682.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  38 in total

Review 1.  Thinking inside the box. To cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems.

Authors:  Lars E Sundstrom
Journal:  EMBO Rep       Date:  2007-07       Impact factor: 8.807

Review 2.  European psychiatry: needs, challenges and structures.

Authors:  Cyril Höschl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

Review 3.  Partial volume effect modeling for segmentation and tissue classification of brain magnetic resonance images: A review.

Authors:  Jussi Tohka
Journal:  World J Radiol       Date:  2014-11-28

Review 4.  Noninvasive and targeted drug delivery to the brain using focused ultrasound.

Authors:  Alison Burgess; Kullervo Hynynen
Journal:  ACS Chem Neurosci       Date:  2013-02-04       Impact factor: 4.418

Review 5.  Harnessing plasticity to understand learning and treat disease.

Authors:  Michael P Kilgard
Journal:  Trends Neurosci       Date:  2012-09-27       Impact factor: 13.837

Review 6.  Stroke prevention in diabetic and other high cardiovascular risk patients.

Authors:  Fadi El-Atat; Tanja Rundek; James R Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

7.  Agomelatine: The evidence for its place in the treatment of depression.

Authors:  Daniela Eser; Thomas C Baghai; Hans-Jürgen Möller
Journal:  Core Evid       Date:  2010-06-15

Review 8.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Subchronic exposure to leachate activates key markers linked with neurological disorder in Wistar male rat.

Authors:  J K Akintunde; G Oboh
Journal:  Environ Sci Pollut Res Int       Date:  2015-09-11       Impact factor: 4.223

10.  Cost of disorders of the brain in Italy.

Authors:  Maura Pugliatti; Patrik Sobocki; Ettore Beghi; Stefano Pini; Giovanni B Cassano; A Carlo Altamura; Sara Pozzoli; Giulio Rosati
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.